Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models

Abstract excerpt

<h4>Background</h4> Diffuse midline glioma (DMG) is an incurable brain cancer without a single FDA-approved drug that prolongs survival. CDK4/6 inhibitors have been evaluated in children with DMG with limited efficacy. Since MAPK pathway activation is upstream of cell proliferation, we hypothesized that MEK inhibitors may increase the anti-tumor effects of CDK4/6 inhibitors. Here, we evaluated the efficacy of the...

Topics

Open a Topic to create a Post that cites this publication.

• Aminopyridines
• Benzimidazoles
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6
• Epithelial-Mesenchymal Transition
• Pyridones
• Pyrimidinones
• Xenograft Model Antitumor Assays

Identifiers and source

Literature Corpus work

ba85c4d7-a88f-5603-b38f-4f146a69eaaf

DOI

10.1101/2025.04.08.647742